The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...